Drug-Induced Lipid Changes

Many drugs besides lipid-lowering drugs affect serum lipid levels in either a potentially harmful or beneficial way, and may therefore increase or decrease the risk of cardiovascular disease. Diuretics, β-blocking agents, progestogens, combined oral contraceptives containing ‘second generation’ progestogens, danazol, immunosuppressive agents, protease inhibitors and enzyme-inducing anticonvulsants adversely affect the lipid profile. They increase total cholesterol, low density lipoprotein cholesterol and triglycerides by up to 40, 50 and 300%, respectively, and decrease high density lipoprotein cholesterol by a maximum of 50%. Conversely, α-blocking agents, estrogens, hormone replacement therapy, combined oral contraceptives containing ‘third generation’ progestogens, selective estrogen receptor modulators, growth hormone and valproic acid show mostly beneficial effects on the lipd profile. Some drugs, for example, isotretinoin, acitretin and antipsychotics, mainly elevate triglyceride levels. Adverse or beneficial effects on serum cholesterol levels do not always translate into a higher or lower, respectively, incidence of cardiovascular disease, because these drugs may influence cardiovascular risk through multiple pathways. In some cases, excessive cholesterol levels occur, for example, with protease inhibitor therapy, and several cases of pancreatitis attributable to drug-induced hypertriglyceridaemia have been reported. Some general guidelines on the management of drug-induced dyslipidaemia can be given. Replacement of the dyslipidaemia-inducing drug by an equivalent alternative therapy is preferred. However, such alternatives are often difficult to find. If there is no equivalent alternative and treatment with the dyslipidaemia-inducing drug must be initiated, monitoring of serum lipid levels is important. If drug use is expected to be long term, the existing guidelines for the management of dyslipidaemia in the general population can be applied to drug-induced dyslipidaemia. In cases of extreme hyperlipidaemia, medication use should be reassessed. Similar content being viewed by others

Kasiske BL, Ma JZ, Kalil RSN, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122: 133–41 Golomb BA, Criqui MH. Antihypertensives: much ado about lipids. Arch Intern Med 1999; 159: 535–7 Hunninghake DB. Effects of celiprolol and other antihypertensive agents on serum lipids and lipoproteins. Am Heart J 1991; 121: 696–701 Weidmann P, de Courten M, Ferrari P. Effects of diuretics on the plasma lipid profile. Eur Heart J 1992; 13: 61G–7G Ames RP. A comparison of blood lipid and blood pressure response during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996; 77: 12B–6B Grimm RH, Flack, JM, Grandits GA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996; 275: 1549–56 Lakshman MR, Reda DJ, Materson BJ, et al. Diuretics and pblockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med 1999; 159: 551–8 Lind L, Berne C, Pollare T, et al. Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. J Hum Hypertens 1995; 9: 137–41 van der Heijden M, Donders SH, Cleophas TJ, et al. A randomized, placebo-controlled study of loop diuretics in patients with essential hypertension: the bumetanide and furosemide on lipid profile (BUFUL) clinical study report. J Clin Pharmacol 1998; 38: 630–5 Campbell N, Brant R, Stalts H, et al. Fluctuations in blood lipid levels during furosemide therapy: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 1998; 158: 1461–3 Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European Study Group. J Hypertens 1998; 16: 1677–84 Howes LG, Lykos D, Rennie GC. Effects of antihypertensive drugs on coronary artery disease risk: a meta analysis. Clin Exp Pharmacol Physiol 1996; 23: 555–8 Fogari R, Zoppi A, Corradi L, et al. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999; 33: 534–9 Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995; 47: 907–10 Hense HW, Doring A, Stieber J, et al. The association of antihypertensive treatment patterns and adverse lipid effects in population-based studies. J Clin Epidemiol 1992; 45: 1423–30 Strickland D, Sprafka JM, Luepker RV, et al. Association of antihypertensive agents and blood lipids in a population- based survey. Epidemiology 1994; 5: 96–101 Helmert U, Shea S. Antihypertensive treatment and serum cholesterol: results of population-based surveys in the German Cardiovascular Prevention Study. Rev Environ Health 1997; 12: 253–60 Goode GK, Miller JP, Heagerty AM. Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995; 345: 362–4 Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739–45 UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk ofmacrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713–20 ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967–75 Rijpkema AH, van der Sanden AA, Ruijs AH. Effects of postmenopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990; 12: 259–85 Miller VT, Muesing RA, LaRosa JC, et al. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I. Obstet Gynecol 1991; 77: 235–40 Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196–204 Lobo RA, Pickar JH, Wild RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol 1994; 84: 987–95 The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial [published erratum appears in JAMA 1995; 274: 1676]. JAMA 1995; 273: 199–208 Mc Manus J, Mc Eneny J, Thompson W, et al. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. Atherosclerosis 1997; 135: 73–81 Baker VL. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am 1994; 21: 271–97 Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991; 73: 373–9 Silfverstolpe G, Gustafson A, Samsioe G, et al. Lipid metabolic studies in oophorectomized women: effects of three different progestogens. Acta Obstet Gynecol Scand 1979; 88Suppl.: S89–S95 Saarikoski S, Yliskoski M, Penttila I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas 1990; 12: 89–97 Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375–81 Ball MJ, Ashwell E, Gillmer MD. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 1991; 44: 223–33 Enk L, Landgren BM, Lindberg UB, et al. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 1992; 24: 85–9 McEwan JA, Griffin M, Fotherby K, et al. Long-term use of depot-norethisterone enanthate: effect on blood lipid fractions. Contraception 1992; 46: 49–60 Fahmy K, Khairy M, Allam G, et al. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 1991; 44: 431–44 Garza-Flores J, De la Cruz DL, Valles de Bourges V, et al. Longterm effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 1991; 44: 61–71 Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63 Vandenbroucke JP. Postmenopausal oestrogen and cardioprotection. Lancet 1991; 337: 833–4 Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13 Kafrissen ME, Corson SL. Comparative review of third-generation progestins. Int J Fertil 1992; 37Suppl. 2: 104–15 Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol 1993; 81: 1034–47 Lobo RA, Skinner JB, Lippman JS, et al. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril 1996; 65: 1100–9 Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism [published erratum appears in Contraception 1998; 57: 420]. Contraception 1998; 57: 189–201 Burkman RT, Robinson JC, Kruszon-Moran D, et al. Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. Obstet Gynecol 1988; 71: 33–8 Burkman RT, Zacur HA, Kimball AW, et al. Oral contraceptives and lipids and lipoproteins: part I — variations in mean levels by oral contraceptive type. Contraception 1989; 40: 553–61 Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93 Hannaford PC, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives. BMJ 1998; 316: 984–7 Hannaford P. Cardiovascular events associated with different combined oral contraceptives: a review of current data. Drug Saf 2000; 22: 361–71 Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives [published erratum appears in Lancet 1999 Oct 23; 354 (9188): 1478]. Lancet 1999; 354: 127–8 Benshushan A, Brzezinski A. Tamoxifen effects on menopause-associated risk factors and symptoms. Obstet Gynecol Surv 1999; 54: 272–8 McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991; 303: 435–7 Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993; 85: 1398–406 Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835–42 Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–7 Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445–51 Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998; 13: 1747–54 de Valk-de Roo GW, Stehouwer CD, Meijer P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999; 19: 2993–3000 Packard CJ, Shepherd J. Action of danazol on plasma lipids and lipoprotein metabolism. Acta Obstet Gynecol Scand 1994; 159Suppl.: 35–40 Rosen T, Johannsson G, Johansson JO, et al. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment: a review paper. Horm Res 1995; 43: 93–9 Cuneo RC, Salomon F, Watts GF, et al. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993; 42: 1519–23 Russell-Jones DL, Watts GF, Weissberger A, et al. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin Endocrinol Oxf 1994; 41: 345–50 Johannsson G, Oscarsson J, Rosen T, et al. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults: influence of gender and Apo(a) and ApoE phenotypes. Arterioscler Thromb Vasc Biol 1995; 15: 2142–50 Leese GP, Wallymahmed M, VanHeyningen C, et al. HDL-cholesterol reductions associated with adult growth hormone replacement. Clin Endocrinol Oxf 1998; 49: 673–7 Leese GP, Wallymahmed M, Wieringa G, et al. Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement. Eur J Endocrinol 1999; 140: 174–9 Lyons F, Laker MF, Marsden JR, et al. Effect of oral 13-cisretinoic acid on serum lipids. Br J Dermatol 1982; 107: 591–5 Zech LA, Gross EG, Peck GL, et al. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin: a prospective study. Arch Dermatol 1983; 119: 987–93 Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985; 313: 981–5 Melnik BC, Bros U, Plewig G. Evaluation of the atherogenic risk of isotretinoin-induced and etretinate-induced alterations of lipoprotein cholesterol metabolism. J Invest Dermatol 1987; 88Suppl. 3: S39–S43 Walker BR, MacKie RM. Serum lipid elevation during isotretinoin therapy for acne in the west of Scotland. Br J Dermatol 1990; 122: 531–7 Barth JH, Macdonald-Hull SP, Mark J, et al. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol 1993; 129: 704–7 Fex GA, Aronsson A, Andersson A, et al. In vivo effects of 13-cis retinoic acid treatment on the concentration of proteins and lipids in serum. Eur J Clin Chem Clin Biochem 1996; 34: 3–7 Lestringant GG, Frossard PM, Agarwal M, et al. Variations in lipid and lipoprotein levels during isotretinoin treatment for acne vulgaris with special emphasis on HDL-cholesterol. Int J Dermatol 1997; 36: 859–62 Neele DM, Buytenhek R, Staels B, et al. No short-term effect of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses LP-A-I and LP-A-I: A-II in healthy volunteers. J Intern Med 1999; 246: 120–2 Vahlquist C, Selinus I, Vessby B. Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis. Acta Derm Venereol 1988; 68: 300–5 Olsen EA, Weed WW, Meyer CJ, et al. Adouble-blind, placebocontrolled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989; 21: 681–6 Gupta AK, Goldfarb MT, Ellis CN, et al. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989; 20: 1088–93 Frati C, Bevilacqua L, Apostolico V. Association of etretinate and fish oil in psoriasis therapy: inhibition of hypertriglyceridemia resulting from retinoid therapy after fish oil supplementation. Acta Derm Venereol 1994; 186Suppl.: 151–3 Vahlquist C, Olsson AG, Lindholm A, et al. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients: results of a double-blind cross-over study. Acta Derm Venereol 1995; 5: 377–80 Omenn GS, Goodman G, Thornquist M, et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res 1994; 54Suppl. 7: S2038–S43 Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150–5 Redlich CA, Chung JS, Cullen MR, et al. Effect of long-term beta-carotene and vitamin Aon serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET) [corrected and republished article originally printed in Atherosclerosis 1999 Apr; 143 (2): 427-34]. Atherosclerosis 1999; 145: 425–32 Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621–7 Brown JH, Murphy BG, Douglas AF, et al. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron 1997; 75: 277–82 Lippuner K, Casez JP, Horber FF, et al. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metab 1998; 83: 3795–802 Quaschning T, Mainka T, Nauck M, et al. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int 1999; 71Suppl.: S235–S7 Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336–45 Meffert H, Brautigam M, Farber L, et al. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 1997; 77: 137–41 Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf 1997; 17: 75–92 Brattstrom C, Wilczek H, Tyden G, et al. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65: 1272–4 Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040–6 Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036–42 Wanner C, Bartens W, Galle J. Clinical utility of antilipidemic therapies in chronic renal allograft failure. Kidney Int 1995; 52 Suppl.: S60–S2 Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1–34 Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093–9 Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–F8 _Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995; 333: 1528–33 Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534–9 Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700–5 Roberts AD, Muesing RA, Parenti DM, et al. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 29: 441–3 Berthold HK, Parhofer KG, Ritter MM, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999; 246: 567–75 Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11: 938–9 Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33: 859–63 Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328 Behrens G, Schmidt H, Meyer D, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1958 Karmochkine M, Raguin G. Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. AIDS 1998; 12: 2499 Stricker RB, Man KM, Bouvier DB, et al. Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection. Lancet 1997; 349: 1745–6 Mirete G, Masia M, Gutierrez F, et al. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Eur J Clin Microbiol Infect Dis 1998; 17: 810–1 Di Martino V, Ezenfis J, Benhamou Y, et al. Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. Aids 1999; 13: 1421–3 Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805–10 Wierzbicki AS, Reynolds TM, Crook MA, et al. Lipid lowering therapy in patients with HIV infection. Lancet 1998; 352: 1782 Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31: 1216–24 Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156: 1270–2 Sasaki J, Funakoshi M, Arakawa K. Lipids and apolipoproteins in patients treated with major tranquilizers. Clin Pharmacol Ther 1985; 37: 684–7 Hussar AE. Coronary heart disease in chronic schizophrenic patients: aclinicopathologic study. Circulation 1965; 31: 919–29 Bergemann N, Ehrig C, Diebold K, et al. Asymptomatic pancreatitis associated with clozapine. Pharmacopsychiatry 1999; 32: 78–80 Calandre EP, Rodriquez-Lopez C, Blazquez A, et al. Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand 1991; 83: 250–3 Zeitlhofer J, Doppelbauer A, Tribl G, et al. Changes of serum lipid patterns during long-term anticonvulsive treatment. Clin Invest 1993; 71: 574–8 Sudhop T, Bauer J, Elger CE, et al. Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a gender-related study. Epilepsia 1999; 40: 480–4 Heldenberg D, Harel S, Holtzman M, et al. The effect of chronic anticonvulsant therapy on serum lipids and lipoproteins in epileptic children. Neurology 1983; 33: 510–3 Reddy MN. Effect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein cholesterol, and apolipoproteins A and B in children with epilepsy. Proc Soc Exp Biol Med 1985; 180: 359–63 Franzoni E, Govoni M, D’Addato S, et al. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia 1992; 33: 932–5 Eiris JM, Lojo S, Del Rio MC, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995; 45: 1155–7 Muuronen A, Kaste M, Nikkila EA, et al. Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study. Br Med J Clin Res Ed 1985; 291: 1481–3 Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823–8 Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–6 Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6

We gratefully acknowledge W.M.M. Verschuren for carefully reading the manuscript. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Mantel-Teeuwisse, A.K., Kloosterman, J.M., van der Zee, A.H.M. et al. Drug-Induced Lipid Changes. Drug-Safety 24, 443–456 (2001). https://doi.org/10.2165/00002018-200124060-00003 Published: Issue date: DOI: https://doi.org/10.2165/00002018-200124060-00003